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Background: Many studies have demonstrated a robust statistical overlap between genes whose transcripts are
reported as Fragile X Mental Retardation Protein (Fmrp)-binding targets and genes implicated in various psychiatric
disorders, including autism. However, it is not clear how to interpret this overlap as the Fmrp protein itself is not
considered to be central to all instances of these conditions.
Findings: We tested whether Fmrp binding may be a proxy for some other features of these transcripts. Reviewing
recent literature on the cross-linking and immunoprecipitation (CLIP)-derived targets of Fmrp in the brain, and the
literature on identifying genes thought to mediate autism and other psychiatric disorders, reveals that both appear
to be disproportionately made up of highly brain-expressed genes. This suggests a parsimonious explanation—that
the overlap between Fmrp targets and neuropsychiatric candidate genes might be secondary to simple features
such as transcript length and robust expression in the brain. Indeed, reanalyzing Fmrp high-throughput sequencing
of RNAs isolated by CLIP (HITS-CLIP) data suggests that approximately 60% of CLIP tag depth can be predicted by
gene expression, coding sequence length, and transcript length. Furthermore, there is a statistically significant overlap
between autism candidate genes and random samples of long, highly brain-expressed genes, whether they are Fmrp
targets or not.
Conclusions: Comparison of known Fmrp-binding targets to candidate gene lists should be informed by both of these
features.
Keywords: FMRP interactome, Autism, Genome-wide associationFindings
Introduction
In 2011, Darnell et al. published a study on the Fragile
X Mental Retardation Protein (Fmrp) that demonstrated
through brute-force biochemistry and elegant informatics,
a fundamental role for Fmrp in stalling of ribosomes in
the brain [1]. Included was a table of the RNAs identified
as bound to Fmrp. While the authors were careful to note
their analysis likely “…underestimates the true number of
Fmrp-regulated mRNAs,” this table has gradually become
taken as the de facto Fmrp regulon - the comprehensive
set of transcripts regulated by Fmrp. Since then, it has* Correspondence: jdougherty@genetics.wustl.edu
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article, unless otherwise stated.become recurrent in the psychiatric genetics literature to
examine the intersection between the risk genes of a disorder
and these Fmrp targets, often demonstrating a significant
overlap between the two (for example, [2-8]). However, while
statistically significant, these results are difficult to interpret.
Does this mean the Fmrp protein is central to all of these
diseases and processes? Or is Fmrp binding serving as a
proxy for some other features of the genes that may parsimo-
niously explain their contribution to genetic risk? Here, we
test a simple alternative explanation for these Fmrp-related
findings: both these Fmrp targets and genes that moderate
neurocognitive traits contain a disproportionate number of
long and highly brain-expressed genes.
Results
There are two key facets of the reported Fmrp targets
that motivated this analysis. First, as highlighted in theMed Central. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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promiscuously, not being strongly restricted to RNAs
with one particular motif in the CNS. Second, Fmrp it-
self is highly expressed throughout the nervous system,
particularly, though not uniquely, in neurons [2]. Thus,
as the confidence of Fmrp binding was dependent on
read-depth, and the protein is both fairly promiscuous in
sequence specificity and ubiquitously expressed in the
brain, the most readily detected transcripts might be
those that present the most opportunity for binding -
those with the longest coding sequence and the highest
expression. Thus, we tested the hypotheses that the re-
ported Fmrp targets disproportionately represent the
most abundant mRNAs in the brain (Figure 1A) and
those with the longest coding sequence (Figure 2A). In
support of this, using a list of genes with the highestFigure 1 The Fmrp targets are highly expressed in the brain, and hig
(A) Histogram of P21 mouse brain RNAseq of Fmrp targets (purple) compa
significantly higher expressed, longer than random, brain-expressed genes
with Fmrp HITS-CLIP counts (0.64). (C) Forest plot of the odds ratio and 95
significantly overlap with a database of autism candidate genes (SFARI db,
genes in autism (rDNV, OR = 3.65, P < 6.1e − 12). Likewise, a sample of rand
significantly overlap with the rDNV and SFARIdb (OR = 1.8-2.2) (D) Histogra
gene sets, each sampled to match the Fmrp target’s expression levels, com
sampled sets were generally less significant than the true Fmrp target list (red
significant (blue line, P < 0.05).expression in the human brain [3], one can demonstrate
that the reported Fmrp targets disproportionately over-
lap with the most highly expressed neural genes in
humans (P < 3e−16, Fisher’s exact test).
To test whether this intersection might sometimes
lead to a statistical overlap between Fmrp targets and
trait-associated genes in the brain, we conducted a sim-
ple experiment examining the overlap between a set of
genes involved in a neurogenetic trait unrelated to Fra-
gile X Syndrome or psychiatric disorder. It has been rec-
ognized that, since body weight tracks with consumptive
behaviors, obesity is strongly influenced by genes that
are expressed in the brain [4]. Thus, we tested the statis-
tical overlap between reported genes for “obesity-related
traits” and the reported Fmrp targets and see a statistical
enrichment of a magnitude not too different from thathly brain-expressed genes overlap with autism candidate genes.
red to random selection brain-expressed genes (grey). Fmrp targets are
(P < 2.2e − 16, t test). (B) Gene expression levels correlate moderately
% confidence intervals for Fisher’s exact test results. The Fmrp targets
OR = 3.4, P < 1.2e − 11), recently characterized rare de novo variant
om genes selected to match the expression of the Fmrp targets also
m of the P values resulting from 1,000 Fisher’s exact tests using random
pared to SFARIdb (top panel) or rDNV genes (bottom panel). Randomly


















Figure 2 The Fmrp targets are long transcripts, and long transcripts overlap with autism candidate genes. (A) Histogram of coding
sequence (Cds) lengths of Fmrp targets (purple) compared to an equal length list of random brain-expressed genes (grey). Fmrp targets are significantly
longer than random brain-expressed genes (P< 2.2e− 16, t test). (B) Cds lengths correlate moderately with Fmrp HITS-CLIP counts (0.48). (C) A sample of
random genes selected to match the expression of the Fmrp targets also significantly overlap with the rDNV and SFARIdb. (D) Histogram of the P values
resulting from 1,000 Fisher’s exact tests using random gene sets, each sampled to match the Fmrp target’s Cds length, compared to SFARIdb (top panel) or
rDNV genes (bottom panel). Sampled sets were generally less significant than the true Fmrp list (red arrow, P< 1.2e− 11, P< 6.1e− 12), but most were
more than nominally significantly (blue line, P< 0.05).
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(P < 0.005,). Thus, the results of our experiment are con-
sistent with the explanation that genes mediating any
neurogenetic trait may show overlap with the reported
Fmrp targets simply because both sets overlap with the
set of genes highly expressed in neural tissue. Indeed,
genes reported for several other neurocognitive traits
also overlap Fmrp targets with nominal (P < 0.05) signifi-
cance, for example, “hippocampal atrophy” (P < 0.009),
“Alzheimer’s disease” (P < 0.022), and “cognitive per-
formance” (P < 0.012).
Darnell et al. suspected a bias towards highly
expressed or longer transcripts in their analysis and re-
ported a very modest correlation between transcript
abundance (cor = 0.1) and number of cross-linking and
immunoprecipitation (CLIP)-seq tags ([1]; Additional file
1: Figure S1). However, their measures of abundance
were based on microarray signal, which can be stronglybiased by features unrelated to RNA abundance (for ex-
ample, probe GC content), and lack the dynamic range
of RNAseq analysis. Analyzing instead with RNAseq
data from postnatal day 21, mouse cortex shows a cor-
relation of 0.64 (Figure 1B) with expression and 0.45
with coding sequence (Cds) length (Figure 2B). Indeed,
we found that a linear regression model incorporating
expression, Cds length, and transcript length could ac-
count for >60% of the variance (r2) in CLIP tag number
(Table 1). We would emphasize that the presence of de-
tectable, albeit weak, motifs in the targets [5] indicates
they are non-random and thus the initial findings were
not exclusively driven by these features. The more likely
explanation was that the sensitivity was limited to the
highly expressed Fmrp targets and that many less abun-
dant (but perhaps equally high affinity) Fmrp targets
might simply have been below the threshold of detec-
tion. In the future, the comprehensive identification of
Table 1 A linear model based on transcript expression and length predicts a substantial proportion of Fmrp HITS-CLIP
data
Linear model Fmrp count >1 Fmrp count >16
n = 7,207 genes n = 1,228 genes
r2 r2 p
Fmrp count ~ transcript abundance 0.41 0.21 p < 2.2e − 16
Fmrp count ~ Cds length 0.21 0.12 p < 2.2e − 16
Fmrp count ~ transcript length 0.23 0.09 p < 2.2e − 16
Fmrp count ~ abundance + length (either) 0.54 0.44 p < 2.2e − 16
Fmrp count ~ abundance + Cds length + transcript length 0.61 0.44 p < 2.2e − 16
Using either all genes with at least one CLIP read, expression (logCPM) or length (also log2) predicts some of the Fmrp CLIP tag depth (left column). A linear
model incorporating all three has an r2 > 0.6. Limiting the analysis only to those genes with high read count (>16), the model still has an r2 > 0.4. All models are
highly significant (P < 2.2e − 16).
Figure 3 Sets of random genes sampled to match both the length and expression overlap autism candidate genes. (A) Scatterplot of all
genes (grey dots) and Fmrp target genes (purple circles) and corresponding contours. (B) Contours of all genes, dark gray, Fmrp target genes
(light gray), and a set of genes sampled to match the Fmrp genes (blue). (C) Lists of genes sampled on length and expression overlap with
autism risk genes approximately as well as Fmrp target genes. (D) Histogram of the P values resulting from 1,000 Fisher’ exact tests using random
gene sets, each sampled to match the Fmrp target’s both on length and expression levels, compared to SFARIdb (top panel) or rDNV genes
(bottom panel). Sampled gene sets were often as significant as the true Fmrp target list (red arrow, P < 1.2e − 11, P < 6.1e − 12).
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proaches to allow greater sensitivity and perhaps cell-
specific normalization for transcript abundance. How-
ever, in the meantime, we tested two candidate gene
lists, the Simons Foundation Autism Research Initiative
(SFARI) database of curated autism candidates (SFAR-
Idb) and the recently identified rare de novo variants in
autism probands (rDNV) [6], to see if a statistically sig-
nificant overlap with Fmrp targets could be reproduced
just using equally sized sets of random genes sampled
to match as best possible the transcript abundance
(Additional file 1: Figure S1) or coding sequence length
(Additional file 2: Figure S2) of the Fmrp target genes.
We found in either case that random samples of abun-
dant transcripts (Figure 1C) or transcripts with long Cds
(Figure 2C) were significantly overlapped with the SFAR-
Idb and rDNV genes, though not to the extent of that of
the Fmrp targets. To make sure our results were not
particular to a single sampling, we sampled 1,000 such
gene lists. Most overlapped significantly with the autism
candidates (Figures 1D and 2D), though again not as sig-
nificantly as the reported Fmrp targets. Very similar re-
sults can be seen by comparing a contingency table
overlapping the Fmrp targets and the rDNV genes rela-
tive to all brain-expressed genes (P < 6.02e − 12) or in-
stead calculating the contingency table for just the genes
with expression in the top quantile (P < 0.0002): gene ex-
pression level alone accounts for some of the overlap be-
tween rDNV genes and Fmrp targets, but not all of it.
However, when instead sampling random gene sets to
match the Fmrp targets simultaneously on Cds length
and expression level (Figure 3), we found that a substan-
tial fraction of the sampled lists showed an equivalent or
greater statistical overlap than the original target Fmrp
list (Figure 3C). Finally, we repeated these analyses but
excluded the Fmrp genes from the sampling pool. Be-
cause the Fmrp genes so strongly monopolize the long
and highly expressed gene space (Figure 3A), it was im-
possible to sample a set of genes that perfectly matched
the two-dimensional distribution of the Fmrp targets
after excluding those genes (Additional file 3: Figure
S3A, B). Nonetheless, a random set of non-Fmrp target
genes, or simply a list of the longest and highest
expressed non-Fmrp target genes, also significantly over-
lapped both of the autism candidate lists (Additional file
3: Figure S3C). This demonstrates that long, highly
expressed genes in the brain tend to overlap with
disease-risk genes, whether they are on the Fmrp target
list or not. It is worth noting that a disproportionate
amount of long and highly brain-expressed genes is not
just a feature of the Fmrp targets, but of course many
other sets of genes important for the functioning of the
nervous system (for example, Gene Ontologies terms for
‘Synapse’ or proteomics studies of synaptic proteins), sosome of the conclusions here extend beyond consider-
ation of just the Fmrp targets. Likewise, genes with
enriched expression in the brain are on average longer
than genes expressed in other tissues [7], and thus any
analysis that identifies long genes may tend to overlap
statistically with brain-expressed genes, Fmrp targets,
autism candidates, synaptic proteins, etc.
Conclusions
We have shown that the overlap between the reported
Fmrp targets and at least two autism candidate gene lists
can be reproduced by simply selecting for similarly long
and highly expressed genes in the brain. This is consist-
ent with long and highly brain-expressed genes also be-
ing more likely to be under selective constraint [8] or
containing critical exons [9] and provides a straightfor-
ward explanation for why the Fmrp target list overlaps
so frequently with sets of genes implicated in psychiatric
disease by genetic studies. It is imaginable that similar
features may explain why the Fmrp target list also fre-
quently overlaps results of brain transcriptomic studies
as well. This parsimonious explanation thus obviates
complex hypotheses which require the Fmrp protein it-
self to be involved in the mechanism for many diverse
disorders or different forms of ASD. Of course, muta-
tions in Fmrp clearly do still cause Fragile X Syndrome,
the most common form of monogenic ASD, and thus
continued research into this protein remains important
for that reason alone.
This model also provides reasonable explanations for
two other puzzles about the Fmrp targets. First, it could
explain why studies of the Fmrp targets in HEK cells
[10] are less concordant with other studies [5] and why
HEK cell data overlaps marginally if at all with psychi-
atric disorder candidate gene lists [11]. The HEK cell
data should be biased towards long, highly expressed
genes in HEK cells, which will likely contain few neural-
specific transcripts. Second, this model might explain
why identifying strong cis motifs or other features in the
RNA that might mediate Fmrp binding has proven chal-
lenging [5]. Efforts to model the affinity of Fmrp for par-
ticular mRNAs will likely be aided by first removing the
variance in the Fmrp CLIP data that can be explained by
transcript length, Cds length, and transcript abundance.
The authors of [1] suspected a bias towards highly
expressed genes, but recognized the data were not avail-
able at that time to adjust for it, particularly if the level
of Fmrp varies substantially across cell types in the
brain. Thus, the definition of the Fmrp targets can prob-
ably now be revisited both with greater sensitivity and
by models incorporating these covarying factors to iden-
tify additional features of the transcripts that account for
the remaining variance in Fmrp binding.
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Fmrp does bind preferentially to those transcripts whose
protein levels most require precise regulation for normal
CNS function. It is not unreasonable that this set of
genes would also be vulnerable to haploinsufficiency
[8,9] and of course be expressed highly in the brain. And
a set of genes needing more precise regulation may in-
deed be selected by evolution to be longer (that is,
allowing more potential sites for regulatory motifs).
Thus, Fmrp binding may have been serving as a useful
proxy for these other features. However, in the interim,
we have provided a table (Additional file 4: Table S1)
with precalculated weightings for length, expression, or
length and expression for measurably brain-expressed
genes. This can be used for drawing random samples for
comparison to candidate gene lists, to help determine
whether the candidate list is enriched in Fmrp targets
specifically and/or long, highly brain-expressed tran-
scripts generally.
Methods
Comparisons to GWAS and GTEX
Eight hundred forty-two Fmrp targets were identified
from Supplemental Table 2 of [1]. Genes associated from
cognitive traits were downloaded from the NHGRI
GWAS Catalog [12]. Highly expressed genes in the brain
were defined as the 842 genes with the highest average
RPKM across all brain samples in the genotype-tissue
expression (GTEX) collection [3] (1/31/13 data release,
summarized to genes, all brain samples averaged). Statis-
tical overlap was calculated in R using the Fisher’s exact
test, right-side probability, genome size of 20,000.
RNAseq
All experiments involving mice were approved by the
Washington University Animal Studies Committee. For
each replicate, cortical dissections were performed on
three C57BL/6 male mice 21 days post birth. Tissue was
homogenized in standard homogenization buffer (10 μL/
mL pH 7.5 tris-Cl (Invitrogen 15567–027), containing
0.25 M sucrose (IBI IB37160), 1 μl/mL RNasin (Promega
N251B), SuperRNasin (Ambion AM2696), protease inhibi-
tor cocktail Tablet 1 per 10 mL (Roche 04693132001),
1 mM tetrodotoxin citrate (Tocris Bioscience 1069), and
0.5 mM DL-dithiothreitol (646563-10X) of which was cen-
trifuged for 10 min at 1,000 rcf. The supernatant was then
treated with the addition of 10X lysis buffer (10% IGEPAL
(Sigma I8896-50ML), 300 mM DHPC (Avanti 850306P),
100 mM HEPES (Sigma H0887), 1.5 M KCl (Ambion
AM9640G), and 50 mM MgCl2 (Ambion AM9530G)) for
10 min and centrifuged again for 15 min at 20,000 rcf.
RNA was collected from 60 μL of supernatant on QIA-
GEN RNeasy MINI Kit (74106) with 2-mercaptoethanol
(Sigma M7522) and DNase treatments (Qiagen 79254).Sequencing libraries were amplified (21 cycles) using
Nugen Amplification Kit Ovation® RNA-Seq System V2
(7102). Standard Illumina adapter ligation, library
preparation, and sequencing were performed on an
Illumina Hi-seq by the Genome Technology Access
Center at Washington University in St. Louis. Result-
ing reads were trimmed for quality and contaminating
adapters. Possible rRNA contamination was filtered
out by aligning with Bowtie2 to rRNA sequences from
GenBank, ENSEMBL, and UCSC’s RepeatMasker
track. Remaining sequences were then mapped to the
Ensembl 75 mouse genome. Counts per million reads
(CPM) for each gene were quantified using HTSeq.
Data represent the average of three biological
replicates.
Comparisons to length and expression
We then intersected this data with Supplemental Table
2C of Darnell et al. for all genes with a matching gene
symbol and extracted Fmrp high-throughput sequencing
of RNAs isolated by cross-linking immunoprecipitation
(HITS-CLIP) tag count (Fmrp.sum), Cds length, and
transcript length. For sampling analyses, we used all
genes with measurable expression in the brain (logCPM
> 2 in RNAseq data), as only brain-expressed genes
could have been captured by a brain HITS-CLIP experi-
ment and further filtered to keep only those genes with
an annotated Cds and transcript lengths (final effective
genome size = 9,544). All variables were converted to
Log2 scale for normality prior to correlation and linear
regression, and for these analyses genes with <1 CLIP
tag were excluded (final gene number, 7207). A spreadsheet
aggregating all of these variables is provided (Additional file
4: Table S1).
Candidate gene lists
For the SFARIdb analysis, we used the list of all unique
genes (gene-score table, as downloaded on 8/7/14);
rDNV genes are from Supplemental Table seven from
[6], the dnv_LGDs_prb column.
Sampling random gene sets
To generate sets of 716 random genes with the same
distribution of expression as the 716 Fmrp genes surviv-
ing the filters above, we computed a kernel density esti-
mate on the logCPM (function ‘density’ in R) as well as
a kernel density estimate on all 9,544 genes and used the
ratio of these to assign probabilities for sampling to all
9,544 genes in the genome based on their expression
levels. A similar sampling was done based using a kernel
estimated from the Cds length or a 2d kernel (function
kde2d) on both length and expression. Fisher’s tests were
calculated as above for overlap between sampled lists
with a genome size of 9,544. For !Fmrp lists, sampling
Ouwenga and Dougherty Molecular Autism  (2015) 6:16 Page 7 of 7was conducted on the 8,828 non-Fmrp genes, but with
the same probabilities as above, or taking those of the
8,828 with the highest probabilities (Top !Fmrp). All
sampling is without replacement.
Additional files
Additional file 1: Figure S1. Sampled distributions for expression
approximately match the distribution of Fmrp genes. The distribution of
the Fmrp target genes (purple) is markedly higher than a set of brain-expressed
genes drawn at random from the genome (grey). Our sampling using our
weightings (blue) can approximate the distribution of the Fmrp genes.
Additional file 2: Figure S2. Sampled distributions for Cds length
approximately match the distribution of Fmrp genes. The distribution of
the Fmrp target genes (purple) is markedly higher than a set of brain-expressed
genes drawn at random from the genome (grey). Our sampling using our
weightings (blue) can approximate the distribution of the Fmrp genes.
Additional file 3: Figure S3. Transcripts sampled jointly for length and
expression cannot completely approximate the Fmrp genes. The 2d
distribution density of the Fmrp target genes (light gray) is markedly
shifted compared to brain-expressed genes in general (dark grey) and
random samples of genes when Fmrp targets are excluded (red, A). Even
taking those with the top remaining probabilities (pink, B), can’t perfectly
match the length and expression of the Fmrp target genes. However, (C)
gene lists sampled after excluding the Fmrp target genes also significantly
overlap with the SFARIdb and rDNV genes.
Additional file 4: Table S1 Data. Columns 1 to 5 from Darnell et al.,
Table S2C, columns of same names. Total length, Cds length, and Fmrp.
sum have been log2 transformed. The Fmrp targets were those with an
FDR < 0.01. Columns 6 to 9 from P21 cortical RNAseq data. Columns 10
to 12 are weightings for each gene by length, expression, or length and
expression to allow sampling for random gene lists that match as best
possible these features of the Fmrp targets.
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